RA
FOLD

Rise Advisors’s Amicus Therapeutics FOLD Stock Holding History

Rise Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,140
Closed -$8.98K – 599
2025
Q3 		$8.98K Buy
1,140
+149
+15% +$1.06K ﹤0.01% 1039
2025
Q2 		$5.68K Hold
991
– – ﹤0.01% 1149
2025
Q1 		$8.09K Buy
991
+933
+1,609% +$8.63K ﹤0.01% 1106
2024
Q4 		$546 Hold
58
– – ﹤0.01% 1096
2024
Q3 		$619 Hold
58
– – ﹤0.01% 1186
2024
Q2 		$575 Hold
58
– – ﹤0.01% 1186
2024
Q1 		$683 Hold
58
– – ﹤0.01% 1202
2023
Q4 		$823 Hold
58
– – ﹤0.01% 537
2023
Q3 		$705 Hold
58
– – ﹤0.01% 562
2023
Q2 		$728 Hold
58
– – ﹤0.01% 595
2023
Q1 		$643 Hold
58
– – ﹤0.01% 711
2022
Q4 		$708 Hold
58
– – ﹤0.01% 686
2022
Q3 		$1K Hold
58
– – ﹤0.01% 627
2022
Q2 		$1K Hold
58
– – ﹤0.01% 633
2022
Q1 		$1K Hold
58
– – ﹤0.01% 601
2021
Q4 		$670 Buy
+58
New +$646 ﹤0.01% 614

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rise Advisors's FOLD Position: Q4 2025 in Review

Rise Advisors sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 1,140 shares — an estimated $8.98K sold.

Rise Advisors first reported a position in FOLD in Q4 2021 and held it in 16 quarters. The position peaked at $8.98K in Q3 2025. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Rise Advisors reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 1,140 Amicus Therapeutics shares in Q4 2025, an estimated $8.98K.
  • Rise Advisors first reported a position in Amicus Therapeutics in Q4 2021 and held it in 16 quarters.
  • Rise Advisors's Amicus Therapeutics position peaked at $8.98K in Q3 2025.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.